Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.

@article{Tohen2005OlanzapineVL,
  title={Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.},
  author={Mauricio Tohen and Waldemar Greil and Joseph R. Calabrese and Gary S. Sachs and Lakshmi N. Yatham and Bruno M{\"u}ller Oerlinghausen and Athanasios Koukopoulos and Giovanni Battista Cassano and Heinz Grunze and Rasmus W. Licht and Liliana Dell’Osso and Angela R Evans and Richard C. Risser and Robert William Baker and Heidi Crane and Martin R.K Dossenbach and Charles L. Bowden},
  journal={The American journal of psychiatry},
  year={2005},
  volume={162 7},
  pages={
          1281-90
        }
}
OBJECTIVE The authors compared the efficacy of olanzapine and lithium in the prevention of mood episode relapse/recurrence. METHOD Patients with a diagnosis of bipolar disorder (manic/mixed), a history of two or more manic or mixed episodes within 6 years, and a Young Mania Rating Scale total score > or =20 entered the study and received open-label co-treatment with olanzapine and lithium for 6-12 weeks. Those meeting symptomatic remission criteria (Young Mania Rating Scale score < or =12; 21… 

Figures and Tables from this paper

Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8‐week open label trial

TLDR
Olanzapine may be an effective, well‐tolerated option for treating acute non‐psychotic depression across a variety of bipolar disorder subtypes.

Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).

TLDR
In patients stabilized on quetiapine plus lithium or divalproex, continued treatment was associated with a significant risk reduction in the time to recurrence of any mood event compared with placebo and lithium ordivalproEx.

Olanzapine in the long-term treatment of bipolar disorder: A systematic review and meta-analysis

TLDR
It is concluded that olanZapine may prevent further manic episodes only in patients who have responded to olanzapine in an acute manic or mixed episode and who have not previously had a satisfactory response to lithium or valproate.

Olanzapine as Maintenance Therapy in Patients with Bipolar I Disorder

TLDR
A more robust efficacy of treatment with olanzapine is suggested in the prevention of relapse into manic episodes than into depressive episodes, and a larger proportion of olanZapine- treated patients than comparator-treated patients experienced clinically important weight gain.

Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study

TLDR
As compliance is crucial for the long-term management of these patients, more attention should be directed towards compliance itself and factors associated with compliance levels in everyday treatment settings.
...

References

SHOWING 1-10 OF 24 REFERENCES

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.

TLDR
Olanzapine demonstrated greater efficacy than placebo in the treatment of acute bipolar mania and was generally well tolerated.

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.

TLDR
Lamotrigine and lithium were superior to placebo for the prevention of mood episodes in bipolar I patients, with lamot Rigine predominantly effective against depression and lithium predominantly effectiveagainst mania.

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.

TLDR
Both lamotrigine and lithium were superior to placebo for the prevention of relapse or recurrence of mood episodes in patients with bipolar I disorder who had recently experienced a manic or hypomanic episode.

A Randomized, Placebo-Controlled 12-Month Trial of Divalproex and Lithium in Treatment of Outpatients With Bipolar I Disorder

TLDR
Divalproex was superior to lithium in longer duration of successful prophylaxis in the study and less deterioration in depressive symptoms and Global Assessment Scale scores, and patients treated with divalproEx had better outcomes than those treated with placebo or lithium on several secondary outcome measures.

Olanzapine versus placebo in the treatment of acute mania

Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients.

TLDR
Lithium appears to be superior in prophylactic efficacy to carbamazepine in bipolar patients not previously treated with mood stabilizers, and should reinforce efforts to put and maintain such patients on treatment with lithium.

Olanzapine versus divalproex in the treatment of acute mania.

TLDR
The olanzapine treatment group had significantly greater mean improvement of mania ratings and a significantly greater proportion of patients achieving protocol-defined remission, compared with the divalproex treatment group.

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

BACKGROUND Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R